| Outcome Measures: |
Primary: Part A: Number of participants with one or more Adverse Event (s) (AEs), and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration., A summary of AEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module., Baseline up to Approximately Week 11|Part B: Number of participants with one or more Adverse Event (s) (AEs), and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration., A summary of AEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module., Baseline up to Week 10|Part A: Number of Participants With Clinically Significant Changes in Vital Signs, Baseline up to Approximately Week 11|Part B: Number of Participants With Clinically Significant Changes in Vital Signs, Baseline up to Week 10|Part A: Number of Participants With Clinically Significant Changes in Safety Laboratory Parameters, Baseline up to Approximately Week 11|Part B: Number of Participants With Clinically Significant Changes in Safety Laboratory Parameters, Baseline up to Week 10|Part A: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3938577, PK: AUC of LY3938577 for intravenous administration, Predose on day 1 up to week 13 post dose|Part A: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3938577, PK: AUC of LY3938577 for SC administration, Predose on day 1 up to week 13 post dose|Part B: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3938577, PK: AUC of LY3938577, Predose on day 1 up to week 13 post dose|Part C: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3938577, PK: AUC of for SC administration LY3938577, Predose on day 1 up to week 13 post dose|Part A: PK: Maximum Observed Concentration (Cmax) of LY3938577, PK: Cmax of LY3938577, Predose on day 1 up to week 13 post dose|Part B: PK: Maximum Observed Concentration (Cmax) of LY3938577, PK: Cmax of LY3938577, Predose on day 1 up to week 13 post dose|Part C: PK: Concentration of LY3938577, Predose on day 1 up to week 13 post dose | Secondary: Part B: Pharmacodynamic (PD): Area under the glucose infusion rate curve (GIR AUC) of LY3938577, Measured at different glucose levels in participants with T1DM, Predose up to day 14 post dose|Part C: PD: Glucose infusion rate (GIR) of LY3938577, Measured at different glucose levels in participants with T1DM, Predose up to day 14 post dose
|
